CD19-directed CAR-T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases
Time: 10:30 am
day: Day Two Track B, AM
Details:
• Optimized autologous CAR-T construct
• Translational data for B-cell depletion and immune reset in autoimmune patients
